A contactless cure: Leveraging telehealth to improve hepatitis C treatment at a safety-net hospital.
chronic disease
hepatitis C
telemedicine
urban population
vulnerable populations
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
26
09
2023
accepted:
15
12
2023
medline:
18
3
2024
pubmed:
19
2
2024
entrez:
18
2
2024
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) causes significant mortality worldwide. HCV is highly curable but access to care is limited for many patients. The Grady Liver Clinic (GLC), a primary care-based HCV clinic, utilizes a multidisciplinary team to provide comprehensive care for a medically underserved patient population in Atlanta, Georgia. The GLC added a telehealth option for HCV treatment at the start of the COVID-19 pandemic. We describe the outcomes of utilizing telehealth in this population. We performed a retrospective chart review of patients who initiated HCV treatment from March 2019 to February 2020 (pre-pandemic) and March 2020 to February 2021 (pandemic). Charts were abstracted for patient demographics and characteristics, treatment regimen, and treatment outcomes. Our primary outcome was HCV cure rate of the pre-pandemic compared to the pandemic cohorts and within the different pandemic cohort visit types. We performed an intention-to-treat (ITT) analysis for all patients who took at least one dose of a direct-acting antiviral (DAA) regardless of therapy completion, and a per-protocol (PP) analysis of those who completed treatment and were tested for HCV cure. SVR12 rates were >95% on ITT analysis, with no significant difference between pre-pandemic and pandemic cohorts. There was also no significant difference within the pandemic group when treatment was provided traditionally, via telehealth, or via a hybrid of these. Our findings support the use of telehealth as a tool to expand access to HCV treatment in a medically underserved patient population.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
176-180Informations de copyright
© 2024 John Wiley & Sons Ltd.
Références
World Health Organization, Global Health Sector Strategy on Viral Hepatitis 2016-2021 Towards Ending Viral Hepatitis. Accessed May 26, 2023. https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf
Centers for Disease Control and Prevention. Viral hepatitis surveillance report 2019. Updated May 14, 2021. Accessed May 26, 2023. https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepC.htm
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral direct acting agent therapy for hepatitis C virus infection. A systematic review. Ann Intern Med. 2017;166(9):637-648. doi:10.7326/M16-2575
Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology. 2020;71(2):686-721. doi:10.1002/hep.31060
Haridy J, Iyngkaran G, Nicoll A, Hebbard G, Tse E, Fazio T. eHealth technologies for screening, diagnosis, and management of viral hepatitis: a systematic review. Clin Gastroenterol Hepatol. 2021;19(6):1139-1150.e30. doi:10.1016/j.cgh.2020.09.011
CMS. Telemedicine: Centers for Medicare and Medicaid Services. 2020. Accessed May 26, 2023. https://www.medicaid.gov/medicaid/benefits/telemedicine/index.html
Serper M, Volk ML. Current and future applications of telemedicine to optimize the delivery of Care in Chronic Liver Disease. Clin Gastroenterol Hepatol. 2018;16(2):157-161.e8. doi:10.1016/j.cgh.2017.10.004
Dupont SC, Fluker SA, Quairoli KM, et al. Improved hepatitis C cure Cascade outcomes among urban baby boomers in the direct-acting antiviral era. Public Health Rep. 2020;135(1):107-113. doi:10.1177/0033354919888228
Veeramachaneni H, Park B, Blakely D, et al. Differences in inpatient and outpatient hepatitis C virus prevalence and linkage to care rates in a safety net hospital hepatitis C screening program. J Gastroenterol Hepatol. 2021;36(8):2285-2291. doi:10.1111/jgh.15492
Hofmeister MG, Rosenthal EM, Barker LK, et al. Estimating prevalence of hepatitis C virus infection in the United States, 2013-2016. Hepatology. 2019;69(3):1020-1031. doi:10.1002/hep.30297
Fluker S, Darby R, McDaniel K, et al. Large-scale, primary care-based hepatitis C treatment in an urban, medically underserved patient population. Public Health Rep. 2023;333549231170205. doi:10.1177/00333549231170205
Miller L, Fluker SA, Osborn M, Liu X, Strawder A. Improving access to hepatitis C care for urban, underserved patients using a primary care-based hepatitis C clinic. J Natl Med Assoc. 2012;104(5-6):244-250. doi:10.1016/s0027-9684(15)30161-9
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Accessed May 26, 2023. http://www.hcvguidelines.org
Butner JL, Gupta N, Fabian C, Henry S, Shi JM, Tetrault JM. Onsite treatment of HCV infection with direct acting antivirals within an opioid treatment program. J Subst Abus Treat. 2017;75:49-53. doi:10.1016/j.jsat.2016.12.014
Read P, Lothian R, Chronister K, et al. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting. Int J Drug Policy. 2017;47:209-215. doi:10.1016/j.drugpo.2017.05.032
Nouch S, Gallagher L, Erickson M, et al. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada. Int J Drug Policy. 2018;59:76-84. doi:10.1016/j.drugpo.2018.06.019
Hepatitis C Virus Infection in Adolescents and Adults: Screening. Updated March 2, 2020. Accessed May 26, 2023. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-c-screening
Neuhaus M, Langbecker D, Caffery LJ, et al. Telementoring for hepatitis C treatment in correctional facilities. J Telemed Telecare. 2018;24(10):690-696. doi:10.1177/1357633X18795361
Keogh K, Clark C, Valery PC, et al. Use of telehealth to treat and manage chronic viral hepatitis in regional Queensland. J Telemed Telecare. 2016;22(8):459-464. doi:10.1177/1357633X16673794
Mera J, Joshi K, Thornton K, et al. Retrospective study demonstrating high rates of sustained virologic response after treatment with direct-acting antivirals among American Indian/Alaskan natives. Open Forum Infect Dis. 2019;6(7):ofz128. doi:10.1093/ofid/ofz128
Rossaro L, Torruellas C, Dhaliwal S, et al. Clinical outcomes of hepatitis C treated with pegylated interferon and ribavirin via telemedicine consultation in northern California. Dig Di Sci. 2013;58(12):3620-3625. doi:10.1007/s10620-013-2810-y
Nazareth S, Kontorinis N, Muwanwella N, Hamilton A, Leembruggen N, Cheng WSC. Successful treatment of patients with hepatitis C in rural and remote Western Australia via telehealth. J Telemed Telecare. 2013;19(2):101-106. doi:10.1258/jtt.2012.120612
Chen WL, Chiu WT, Wu MS, Hsu MH, Tsa SH. Translational research of telecare for the treatment of hepatitis C. Biomed Res Int. 2014;2014:195097. doi:10.1155/2014/195097
Cooper C, Hatashita H, Corsi DJ, Parmar P, Corrin R, Garber G. Direct-acting antiviral therapy outcomes in Canadian chronic hepatitis C telemedicine patients. Ann Hepatol. 2017;16(6):874-880. doi:10.5604/01.3001.0010.5277
Jimenez-Galan G, Alia-Alia C, Vegue-Gonzalez M, et al. The contribution of telemedicine to hepatitis C elimination in a correctional facility. Rev Esp Enferm Dig. 2019;111(7):550-555. doi:10.17235/reed.2019.6152/2018
Morey S, Hamoodi A, Jones D, et al. Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine. J Viral Hepat. 2019;26(1):101-108. doi:10.1111/jvh.13017
Schulz T, Kanhutu K, Sasadeusz J, Watkinson S, Biggs A. Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era. J Telemed Telcare. 2020;26(3):180-185. doi:10.1177/1357633X18806651
Case LW, J, Ryan Y. Comparison of hepatitis C treatment outcomes between telehepatology and specialty care clinics in the era of direct-acting antivirals. J Telemed Telecare. 2021;27(7):463-468. doi:10.1177/1357633X19885750